ECYT Shares Ride the Wave of Enthusiasm, Up 100%
Endocyte May Get Up to $1B from Merck for Cancer Drug
By Marie Powers
Tuesday, April 17, 2012
After being drubbed in December 2011 following inconclusive data from a Phase IIb study, Endocyte Inc.'s cancer drug EC145 (vintafolide) made a 180-degree turn, attracting a potential $1 billion deal with Merck & Co. Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.